BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11719396)

  • 1. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.
    Bunworasate U; Arnouk H; Minderman H; O'Loughlin KL; Sait SN; Barcos M; Stewart CC; Baer MR
    Blood; 2001 Dec; 98(12):3492-4. PubMed ID: 11719396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
    Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
    Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
    Alsabeh R; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors.
    Vandermolen L; Rice L; Rose MA; Lynch EC
    Arch Intern Med; 1988 Mar; 148(3):653-6. PubMed ID: 3341866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
    Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin receptor in myelodysplastic syndrome and leukemia.
    Takeshita A; Shinjo K; Naito K; Ohnishi K; Higuchi M; Ohno R
    Leuk Lymphoma; 2002 Feb; 43(2):261-4. PubMed ID: 11999556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
    Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes.
    Mittelman M; Gardyn J; Carmel M; Malovani H; Barak Y; Nir U
    Leuk Res; 1996 Jun; 20(6):459-66. PubMed ID: 8709617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
    Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Oberg G; Osterborg A; Ost A
    Blood; 1998 Jul; 92(1):68-75. PubMed ID: 9639501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
    Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
    Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome.
    Aoki I; Higashi K; Homori M; Chikazawa H; Ishikawa K
    Am J Hematol; 1990 Sep; 35(1):6-12. PubMed ID: 2389770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
    Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
    Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells.
    Goselink HM; Williams DE; Fibbe WE; Wessels HW; Beverstock GC; Willemze R; Falkenburg JH
    Blood; 1992 Aug; 80(3):750-7. PubMed ID: 1638026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.
    Terpos E; Mougiou A; Kouraklis A; Chatzivassili A; Michalis E; Giannakoulas N; Manioudaki E; Lazaridou A; Bakaloudi V; Protopappa M; Liapi D; Grouzi E; Parharidou A; Symeonidis A; Kokkini G; Laoutaris NP; Vaipoulos G; Anagnostopoulos NI; Christakis JI; Meletis J; Bourantas KL; Zoumbos NC; Yataganas X; Viniou NA;
    Br J Haematol; 2002 Jul; 118(1):174-80. PubMed ID: 12100145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin as an independent prognostic factor in myelodysplastic syndromes.
    Boyko O; Simonova M; Knysh N; Danysh O; Vygovska Y; Masliak Z
    Exp Oncol; 2021 Mar; 43(1):41-45. PubMed ID: 33785713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
    Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
    Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.